1. Home
  2. Companies
  3. FemHealth Ventures
FV

FemHealth Ventures

About

As part of our investment approach, we developed a structured evaluation process, the “FemHealth Framework.” The first element (re)imagines women’s health as conditions appearing only in women, mostly in women, and differently in women.

This concept from the FemHealth Framework (© 2019 FemHealth Ventures) was first published in 2019 and is increasingly thought of as a new lens through which to view women’s health. At FemHealth Ventures, we are excited about the increasing adoption of this broader definition of women’s health and the exciting new treatments it will engender.

Only in Women

Some conditions appear only in women.

Examples include:

  • endometriosis
  • polycystic ovarian syndrome
  • cervical cancer

Mostly in Women

Some conditions appear mostly in women.

Examples include:

  • breast cancer
  • lupus
  • multiple sclerosis

Differently in Women

Some conditions appear differently in women.

Examples include:

  • heart disease
  • diabetes
  • asthma

Every cell has a sex

A universe of possibilities is opened in women’s health when we start with the most basic building block: our cells.

Each of the 30 trillion cells in a woman’s body has a different chromosomal makeup than a man.

For example, a skin cell from a woman will have XX chromosomes, but a skin cell from a man will have XY chromosomes. This difference between women and men holds true throughout every single cell in the body.

As a result, even the same disease can present differently in women versus men and require distinct treatment paradigms.

Women’s health is more than “bikini medicine.”

The term “bikini medicine” generally refers to conditions treated by obstetricians or gynecologists.

We’ve (re)imagined women’s health as a broad spectrum of conditions that can impact the whole body, ranging from ovarian cancer, to autoimmune disease, to cardiovascular disease, and everything in between.

A multitude of possibilities for innovation in women’s health exist. And we are here to help bring them to life.

Similar companies

FO

Forbion

Forbion is a leading European venture capital firm that helps companies bridge research and development through the team’s expertise in drug development and company building. Forbion is signatory to the United Nations Principles for Responsible Investment further demonstrating our philosophy that investments in companies should positively impact the health and well-being of patients. Main areas of scientific interest Forbion contributes to the health and well-being of patients worldwide. Our companies have positively affected almost half a million patients in the areas of: Life Sciences Autoimmune & Inflammation Cardiovascular/Metabolic Central nervous system Digestive & Renal Oncology Ophthamology Orphan/rare disease Respiratory BioEconomy Food Agriculture Materials Environmental Technologies Forbion then and now Forbion was born out of ABN AMRO Capital Life Sciences. Today, to emphasize its value-add beyond merely providing capital, we are simply known as Forbion. For more than two decades, our investment team has built an impressive track record of sourcing, building and guiding life-sciences companies resulting in many breakthrough therapies and valuable exits. Forbion currently manages €3 bn across nine funds. As of October 2022, Forbion holds 43 active portfolio companies bringing its investments to 95 companies to date with 46 employees. Forbion’s investors include the European Investment Fund (EIF), notably through its European Recovery Programme (ERP), LfA, the Dutch Venture Initiative (DVI) and AMUF facilities, and the Kreditanstalt für Wiederaufbau (KFW) through the ERP – Venture Capital Fondsfinanzierung facility. € 3bn across 9 funds € 750m Forbion Ventures VI € 600m Forbion Growth Opportunities Fund II 43 active portfolio companies

4 jobs
AV

Amgen Ventures

Amgen Ventures has made >70 INVESTMENTS placing >$400M of the $625M Amgen has committed to support healthcare innovation and interconnectivity at all stages. Amgen Ventures offers us a unique conduit to identify and support key innovators in healthcare at early stages of translational sciences by providing investment capital and access to Amgen’s vast experience in developing leading drugs. AREAS OF INVESTMENTTHERAPEUTICS: Identify promising pipeline assets in Amgen’s therapeutic areas: oncology, immune- oncology, cardiovascular, inflammation, bone health, nephrology, metabolic disorders, and neuroscience. DRUG DISCOVERY & EMERGING TECHNOLOGIES: Improve the discovery process with new technologies including cell therapies, gene-editing and gene-therapies, regenerative medicine, and drug delivery. DIGITAL HEALTHCARE SERVICES, INFORMATION & ANALYTICS: Enhance Amgen medicines by improving real world outcomes and delivering greater value to healthcare systems, doctors, and patients.

AV

Angelini Ventures

We build and invest in companies that positively impact human health with smart solutions, breakthrough science and technology. Our focus is on innovation in digital healthcare, connected medical devices, and life sciences We focus on therapeutic and preventive technology solutions addressing unmet needs in some of the most vulnerable segments of society: women, children and the elderly. Digital transformation will continue to shape our lives and has the potential to transform care. We aim to build and support Digital Health & Life Sciences companies working to make healthcare smarter, using data to improve care and outcomes, and reinventing the patient journey. Our vision for the future of healthcare guides our investment strategy. A data driven digital transformation will shape the future of healthcare. The traditional biopharma model will evolve into an integrated model, where prevention, precision cure, and care management will coexist in a highly personalized patient-centric solution. Our goal is to support the creation of life transforming care products and therapies. We believe the future of healthcare lies in supporting the next-generation of founders and teams who will lead us there. What do we look for?Innovation and groundbreaking opportunities in our sectors of focus: digital health, life sciences, tech-enabled care delivery, and connected devices Innovative treatments for Central Nervous System (CNS) disorders, in particular neurodevelopmental disorders, mental health and epilepsy Founders and teams with domain expertise who seek collaborative investment partners Investments that span development and commercial phases, with a focus on early stage opportunities (Pre-Seed to Series A). Our investment approachOur investment approach combines direct investments in early-stage companies with venture creation from bold ideas in global innovation hubs Our goal is to enable talented entrepreneurs to scale more quickly and effectively through access to our capital, enterprise capabilities and consumer touchpoints, while offering expertise and insights from Angelini’s unique perspective. We invest primarily across Europe, North America and Israel, recognizing that healthcare technology innovation is occurring in many cities around the world. We have committed €300M for investments and company creation in digital health and life sciences. What do we commit to you?Active and involved healthcare investors who operate with integrity, approachability, and transparency A team of passionate healthcare and venture capital experts diverse in demographic and experience A track record of success and experience navigating the ups and downs of early-stage company building Access to a world-class advisory board to leverage C-level experience, expertise, and leadership in healthcare

MA

Mirae Asset Capital Life Science

Mirae Asset Capital Life Science was formed in 2023 as a joint venture between Mirae Asset Capital and Mirae Asset Global Investments. It is the first and only U.S. affiliate for Mirae Asset dedicated to investment in Life Science. Near-Term ValueThe majority of our investments will be Series A/B and entering the clinic within a few years to generate real value with clinical proof of concept We believe companies at this stage maximize returns given the risk; we remain open to seed opportunities where there is a clear path to value and Series C opportunities if the valuation and resulting equity ownership support meaningful returns to our investors We aim to find the right mix between first-in-class and best-in-class assets with meaningful market share and evaluate both platform and single asset approaches Calculated RiskWe are modality agnostic when it comes to therapeutics and incredibly opportunistic with diagnostics Our interest in digital health involves using AI/ML tools (e.g. quantum computing, generative biology/chemistry) for drug discovery or protein engineering We co-invest with top-tier life science investors who we know and have worked with before and leverage our operational experience to find strong management teams with excellent track records relevant to the company they are building We aim to be active investors by securing board roles whenever possible; this is a role that is familiar to us and helps mitigate risk to our investors by helping to shape the course of our investments Innovative yet Validated ModalitiesWe have selected five core therapeutic sectors to focus our investments: Oncology, Immunology, CV/Metabolic, CNS/Ophthalmology, and Rare/Genetic Disease For each of the above sectors we have defined various focus areas defined by a unique combination of validation, unmet need, market potential, and acquisition/public market interest We seek to limit biological and technical risk and prioritize small molecule, antibody approaches (includes mAbs, bsAbs/TCEs, ADCs, radiotherapeutics), and nucleic acid therapeutics (siRNA, ASOs) across these sectors Rigorous EvaluationWe leverage the combined scientific background of our team and our affiliates in Asia (medicinal chemistry, pharmacology, structural biology) to perform rigorous evaluation of each investment We prepare a comprehensive diligence memo for each investment that includes a thorough evaluation of the science, pipeline, finance, management, board, investors, operations, regulatory, IP, clinical development, and potential return to our investors We conduct calls with relevant Key Opinion Leaders for every opportunity to ensure we have the most informed and updated views from the leading voices in the field

CI

Cross-Border Impact Ventures

Cross-Border Impact Ventures is an impact venture capital firm on a mission to revolutionize venture capital investing in health technology. We work with visionary teams to leapfrog access to world leading affordable technologies for women, children and adolescents. Health technologies are more scalable than ever before. The time is now to take a global tailored approach in this sector. OUR INVESTMENT UNIVERSE We look for audacious companies commercializing globally relevant medical devices, diagnostics, therapeutics and digital health innovations that are prioritizing huge market opportunities in women, children and adolescent health. We value real world and clinical data. We focus on 4 key sectors: Sexual and reproductive health, Maternal, newborn and child health, General health, including chronic diseases, and Health software infrastructure. We invest in companies addressing gender health inequalities. Positive impact and financial returns are not mutually exclusive. We seek opportunities that offer both high impact & high returns. OUR IMPACT We believe good health is a right that should not be restricted by gender, age, race, wealth and borders. We hold ourselves to the highest standard of impact investing and implement recognized impact management processes. We invest with a gender and diversity lens. WE ARE ENABLERS We are specialists in women, children and adolescent health with deep expertise in health technology. We are hands-on investors and support our exceptional management teams with access to new markets, unique forms of capital and health technology expertIse in North America, Europe as well as global markets. WE UNLOCK GLOBAL IMPACT OPPORTUNITIES Cutting edge technologies take decades to reach underserved communities. We work with management teams to fast track the process.

SV

Sanofi Ventures

We invest in the innovators behind the miracles of science who are passionate about improving human health. Sanofi Ventures serves as an entry point to the innovation ecosystem for Sanofi, strategically investing in early-stage transformational science and technology, when companies are too early to partner with or acquire. Our Approach As the corporate venture capital arm of Sanofi, we invest in top-tier biotech and digital health companies that focus on helping patients and transforming the practice of medicine. We invest across all stages of the private company lifecycle, from Seed to Series B and beyond, while leading financings, serving on boards, and taking pride in working alongside portfolio companies to drive long-term value through future financings and IPO. How We Work Think of us like institutional venture capitalists with an added bonus: in addition to our investment, we aim to offer our portfolio companies select access to Sanofi’s expertise and capabilities in science, preclinical and clinical development, regulatory, data analytics, manufacturing, market access, and commercialization. Our goal is to foster strong relationships over time so when our portfolio company is ready to consider a partnership or acquisition, our colleagues on the BD and M&A teams can be a first and last call. We move quickly, we don’t believe in drawn-out processes, and we always aim to provide thoughtful feedback. Our Investment Focus We invest in early-stage biotech and digital health companies of strategic interest to Sanofi. We seek to accelerate all strategic focus while reaching into novel and emerging areas of science and technology. Here are some of the areas that we currently are thinking about: Rare diseases Immunology and inflammation Oncology Cell and gene therapy Vaccines Digital health and data science We can't do it alone - we would love to hear how we can team up to improve human health for people everywhere!